Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL
Authors
Keywords
-
Journal
GENE THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-15
DOI
10.1038/s41434-020-0171-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology
- (2018) Maria G. Crespo-Leiro et al. EUROPEAN JOURNAL OF HEART FAILURE
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
- (2018) Christian Hinderer et al. HUMAN GENE THERAPY
- Gene Therapy for Cerebral Adrenoleukodystrophy
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial
- (2017) Jean-Sébastien Hulot et al. EUROPEAN JOURNAL OF HEART FAILURE
- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
- (2017) Jerry R. Mendell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
- (2017) Lindsey A. George et al. NEW ENGLAND JOURNAL OF MEDICINE
- AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
- (2017) Savita Rangarajan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
- (2016) Barry Greenberg et al. LANCET
- Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure
- (2014) Barry Greenberg et al. JACC-Heart Failure
- Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure
- (2013) Krisztina Zsebo et al. CIRCULATION RESEARCH
- Targeted Sarcoplasmic Reticulum Ca 2+ ATPase 2a Gene Delivery to Restore Electrical Stability in the Failing Heart
- (2012) Michael J. Cutler et al. CIRCULATION
- Plasticity of Surface Structures and β 2 -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure
- (2012) Alexander R. Lyon et al. Circulation-Heart Failure
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)
- (2011) Mariell Jessup et al. CIRCULATION
- SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure
- (2011) Alexander R. Lyon et al. Circulation-Arrhythmia and Electrophysiology
- Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals
- (2008) M J Byrne et al. GENE THERAPY
- Reversal of Cardiac Dysfunction After Long-Term Expression of SERCA2a by Gene Transfer in a Pre-Clinical Model of Heart Failure
- (2008) Yoshiaki Kawase et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started